Topic: Radiopharmaceuticals

Metastasis-Directed Therapy: Radiation Oncology Updates and Perspective

Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses metastasis-directed therapy (MDT) as a potential treatment option for oligometastatic prostate cancer. He reviews typical management of metastatic cancer and describes how MDT can minimize the toxicity of systemic therapy, then addresses future treatment options with stereotactic ablative radiotherapy (SABR). Radiation and other local therapies are used for palliation of metastases but can also alter the course of tumor development. Dr. Finkelstein explains that MDT can be particularly beneficial in oligometastatic prostate cancer if the metastases are at a point where both the primary tumor and metastases can be treated together and likely cured. Lastly, he concludes that MDT via SABR could be employed concurrently with other treatments such as androgen deprivation therapy (ADT), chemotherapies, and radiopharmaceuticals, and that further research is necessary.

Read More

Radiation Therapy: What’s New for Localized Disease

Christina E. Henson, MD, describes how recent trial-based research has established new standards in prostate cancer radiotherapy. She discusses several modes of therapy, including hypofractionation, metastasis-directed therapy for treating oligometastatic disease, and pelvic nodal irradiation, noting that research has shown them to be effective treatments in a variety of disease states. Ultra-hypofractionation has been proven to have an increased therapeutic ratio compared to other methods, as well as a 5-year failure-free survival of 84% across all trials. Elective nodal radiation up to L4 or higher is now recommended to maximize treatment outcomes. Metastasis-directed therapy has been proven to help patients even with limited disease burden and should be viewed as an option in these cases, though it is not always successful.

Read More

M0 CRPC: Treatment Options and Emerging Concepts

Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of androgen receptor antagonists in treating patients with non-metastatic (M0) castrate-resistant prostate cancer (CRPC). She goes on to discuss how before these three pivotal trials, treatment for patients with M0 CRPC remained a bit of a mystery. However, the results of these trials demonstrated treating men with these agents who had a PSA doubling time less than ten months significantly improved their metastasis-free survival compared to men in the control arm.

Read More

MRI First: The Role of MRI in Biopsy Naïve Patients

Monju J. Patel, MD, discusses how variation in mpMRI image quality and radiologist interpretation and experience, as well as technicalities of the PIRADS-2 scoring system, can significantly impact radiologists’ ability to detect lesions suspicious for prostate cancer. He goes on to present several case studies on how to utilize mpMRI’s strong specificity to evaluate extraprostatic extension and anterior transition zone tumors, and how to use mpMRI to evaluate the entire pelvis for possible metastatic disease. Finally, Dr. Patel considers the detection pitfalls of mpMRI, such as differentiating benign anatomy versus a malignancy, abnormalities that exist in the central zone, and how to identify diffuse, infiltrative carcinoma.

Read More

Exosomal Liquid Biopsy in Prostate Cancer: Role in Prostate Biopsy Decision-Making

Judd Moul, MD, Professor of Surgery and Anesthesiology as well as the James H. Semans, MD, Distinguished Professor of Urologic Surgery at Duke University School of Medicine, discusses the ExoDx Prostate Intelliscore (EPI), a urine-based liquid biopsy test with high negative predictive value (NPV) that may be a useful prostate cancer (PCa) diagnostic tool for primary care providers (PCPs). He emphasizes EPI’s relative ease of use, noting that it is necessary to have simple screening procedures in order to take the burden off of over-stretched urologists.

Read More

PSMA-11 PET: Atypical Paths to FDA Approval and Academic NDAs

Thomas Hope, MD, Assistant Professor in Residence in Abdominal Imaging and Nuclear Medicine in the Department of Radiology at the University of California, San Francisco, explains how an academic institution successfully submits a new drug application (NDA) to the US Food and Drug Administration (FDA), using the NDA for prostate-specific membrane antigen (PSMA) 11 as an example. He notes the limitations that academia has in this area, and recommends that, going forward, institutions design imaging studies so that they report usable detection rates and have blinded readers.

Read More

Current and Emerging Role of Radiogenomics

John Feller, MD, Founding Partner and Medical Director at Desert Medical Imaging, gives an overview of radiogenomics’ current and possible future role in prostate cancer care. He notes the recent promising results of multiparametric MRI (mpMRI) from trials, which have shown that using mpMRI before transrectal ultrasound-guided (TRUS) biopsy can decrease the number of unnecessary biopsies, limit detection of insignificant cancer, and improve detection of significant cancer. These have influenced the updated 2019 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer. Dr. Feller further discusses other biomarkers for risk stratification and promising research on radiogenomics in the setting of focal therapy.

Read More
Loading

Join the GRU Community

- Why Join? -